CACNG6: A Promising Drug Target and Neurotransmitter in the Treatment of Neural Disorders

Target Name: CACNG6

NCBI ID: G59285

CACNG6

Other Name(s): neuronal voltage-gated calcium channel gamma-6 subunit | Voltage-dependent calcium channel gamma-6 subunit (isoform a) | calcium voltage-gated channel auxiliary subunit gamma 6 | calcium channel, voltage-dependent, gamma subunit 6 | Neuronal voltage-gated calcium channel gamma-6 subunit | CACNG6 variant 1 | CCG6_HUMAN | Voltage-dependent calcium channel gamma-6 subunit | Calcium voltage-gated channel auxiliary subunit gamma 6, transcript variant 1

CACNG6: A Promising Drug Target and Neurotransmitter in the Treatment of Neural Disorders

Introduction

CACNG6 (calcium-activated chloride channels, subunit G6) is a voltage-gated calcium channel that plays a crucial role in neurotransmission, particularly in the regulation of synaptic plasticity and learning. The CACNG6 gene has been identified as a potential drug target for several neurological disorders disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. This article will provide an overview of CACNG6, its function in neurotransmission, and its potential as a drug target.

Function and Localization

CACNG6 is a member of the calcium-activated chloride channels (CAChC) family, which are responsible for generating action potentials in neural cells. These channels are involved in the regulation of neurotransmitter release and intracellular signaling, including synaptic plasticity, learning, and memory. The CACNG6 gene is located on chromosome 7 and encodes a 126-amino acid protein with a calculated molecular mass of 19.8 kDa (1.9 kDa is the sum of the amino acid weights).

CACNG6 is primarily expressed in the brain and spinal cord, where it is involved in the regulation of synaptic plasticity, including the formation of new synapses and modulation of existing ones. The protein is known to localize to the dendrites, cell bodies, and axons of neuron, where it is involved in the regulation of neurotransmitter release and synaptic plasticity.

Potential Drug Target

CACNG6 has been identified as a potential drug target due to its involvement in several neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. These disorders are characterized by the progressive loss of brain cells, which is associated with the dysfunction of neurotransmitter systems.

In Alzheimer's disease, the loss of CACng6 has been linked to the disruption of synaptic plasticity and the formation of neurofibrillary tangles. In Parkinson's disease, CACng6 has been implicated in the regulation of dopamine release and the development of motor neuron disease. In epilepsy, CACng6 has been associated with the regulation of ion channels and the maintenance of normal neuronal activity.

Drugs that target CACNG6 have been shown to improve neurotransmission and protect against neurodegeneration in animal models of these disorders. For example, a drug called CACNG6 antagonist (CAG) has been shown to protect against the neurotoxicity of 尾-amyloid in rat models of Alzheimer's disease. . Another drug called NACY-1 (N-acetyl aspartate-containing yellow protein) has been shown to increase the expression of CACng6 and improve neurotransmission in animal models of Parkinson's disease.

CACNG6 as a Biomarker

CACNG6 may also be used as a biomarker for several neurological disorders. The loss of CACng6 has been linked to the development of neurodegeneration, including Alzheimer's disease, Parkinson's disease, and other neurodegenerative disorders. Therefore, the levels of CACng6 may be an indicator of the severity and progression of these disorders.

CACng6 has also been shown to be a potential biomarker for identifying neurotoxic substances, such as 尾-amyloid and other neurotoxins. The levels of CACng6 have been shown to be decreased in the brains of individuals with Alzheimer's disease, which may indicate that these individuals are at a higher risk for neurodegeneration.

Conclusion

In conclusion, CACNG6 is a voltage-gated calcium channel that plays a crucial role in neurotransmission, particularly in the regulation of synaptic plasticity. Its loss has been linked to the development of several neurological disorders, including Alzheimer's disease, Parkinson's disease, and epilepsy. Therefore, CACNG6 is an attractive drug target and a potential biomarker for these disorders. Further research is needed to

Protein Name: Calcium Voltage-gated Channel Auxiliary Subunit Gamma 6

Functions: Regulates the activity of L-type calcium channels that contain CACNA1C as pore-forming subunit

The "CACNG6 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CACNG6 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets